Anthracyclines and heart failure

New England Journal of Medicine

Volumn 368, Issue 12, 2013, Pages 1154-1156

  Sawyer, Douglas B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIOXIDANT; DAUNORUBICIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; RAZOXANE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CARDIOTOXICITY; CELL DEATH; DNA DAMAGE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL;

EID: 84875198662     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1214975     Document Type: Article

References (3)

1. Unverferth BJ, Magorien RD, Balcerzak SP, Leier CV, Unverferth DV. Early changes in human myocardial nuclei after doxorubicin. Cancer 1983;52:215-21. (Pubitemid 13063160)
2. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-42.
3. Lyu YL, Lin C-P, Azarova AM, Cai L, Wang JC, Liu LF. Role of topoisomerase IIβ in the expression of developmentally regulated genes. Mol Cell Biol 2006;26:7929-41. (Pubitemid 44630993)